Abstract:A series of 1H‐benzimidazole‐4‐carboxamide PARP‐1 inhibitors using different saturated nitrogen‐containing heterocycles as linker groups was designed synthesized and evaluated its anti‐proliferation activities of MDA‐MB‐436 cell to obtain the preferred structures of linker group and terminal group in the AD site. PARP‐1 inhibitors have been successfully applied in the clinical treatment of various cancer. Side effects and drug resistant cases were reported, and more effective PARP‐1 inhibitors were required. However, studies on the AD site of PARP‐1 inhibitors are currently incomplete. Therefore, to synthesize more potential candidate PARP‐1 inhibitors and disclose some AD site SAR of the PARP‐1 inhibitors, herein, a series of 2‐phenyl‐benzimidazole‐4‐carboxamide derivatives using different saturated nitrogen‐contained heterocycles as linker group (6a‐6t) have been designed, synthesized and evaluated PARP‐1 inhibitory activity and proliferation inhibitory against BRCA‐1 mutant MDA‐MB‐436 cell line in vitro. The results showed 6b (IC50 = 8.65 nM) exhibited the most PARP‐1 enzyme inhibitory activity comparable with Veliparib (IC50 = 15.54 nM) and Olaparib (IC50 =2.77 nM); 6m exhibited the strongest MDA‐MB‐436 cell anti‐proliferation activity (IC50=25.36±6.06 μM) comparable with Olaparib (IC50 = 23.89±3.81 μM). The compounds 6b, 6r, and 6m could be potential candidates for effective PARP‐1 inhibitors and valuable for further optimization. The analysis of activity data also showed that the holistically anti‐proliferation activity of the 1,4‐diazepane group was about~2 fold than that of the piperazine group. Meanwhile, the terminal 3‐methyl‐furanyl group exhibited the most robust PARP‐1 inhibitory and anti‐proliferation activity. It's hoped that the results could benefitable for further optimization of PARP‐1 inhibitors. Furthermore, we note that some compounds (6d,6g,6n,6p,6s) showed poor PARP‐1 inhibitory (>500 nM) but relatively good anti‐proliferation activity, which indicates the proliferation inhibitory mechanism against MDA‐MB‐436 cell line was worth investigating in‐depth.

Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis

Synthesis and Biological Evaluation of Piperidyl Benzimidazole Carboxamide Derivatives As Potent PARP-1 Inhibitors and Antitumor Agents

In Silico Study Simulation Targeting PARP-1 and In Vitro Study Validation Using Cancer Cell Lines

The 7-aminoquinolinone derivatives as PARP1 inhibitors

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

Discovery of Novel Bromophenol Thiosemicarbazone Hybrids As Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

Design, Synthesis, and Evaluation of 1H‐benzo[d]imidazole‐4‐carboxamide PARP‐1 Inhibitors Using Different Saturated Nitrogen‐Contained Heterocycle as linker Group

PARP1 Inhibitors: Antitumor Drug Design

Design, Synthesis and Evaluation of Phthalazinone Thiohydantoin-Based Derivative As Potent PARP-1 Inhibitors.

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Synthesis and biological evaluation of a tumor-selective degrader of PARP1

Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone

Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor

Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

Design, Synthesis and Biological Evaluation of Pyridazino[3,4,5-De]quinazolin-3(2h)-one As a New Class of PARP-1 Inhibitors.